Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.19 CAD
Change Today 0.00 / 0.00%
Volume 0.0
BLU On Other Exchanges
Symbol
Exchange
Toronto
Frankfurt
As of 3:35 PM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

bellus health inc (BLU) Snapshot

Open
C$1.21
Previous Close
C$1.19
Day High
C$1.21
Day Low
C$1.07
52 Week High
09/2/14 - C$1.80
52 Week Low
05/12/14 - C$0.72
Market Cap
56.4M
Average Volume 10 Days
19.7K
EPS TTM
C$-0.30
Shares Outstanding
47.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BELLUS HEALTH INC (BLU)

Related News

No related news articles were found.

bellus health inc (BLU) Related Businessweek News

No Related Businessweek News Found

bellus health inc (BLU) Details

BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. It is also developing KIACTA for the treatment of chronic sarcoidosis. The company’s clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome caused to Shiga toxin-producing E. coli, as well as has a research project to identify drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience Inc. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Founded in 1993

bellus health inc (BLU) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$319.0K
Vice President of Finance
Total Annual Compensation: C$172.4K
Senior Vice President of Drug Development
Total Annual Compensation: C$325.0K
Vice President of Business Development
Total Annual Compensation: C$176.8K
Compensation as of Fiscal Year 2014.

bellus health inc (BLU) Key Developments

BELLUS Health Inc. Reports Consolidated Earnings Results for the Full Year Ended December 31, 2014

BELLUS Health Inc. reported consolidated earnings results for the full year ended December 31, 2014. For the period, the company reported net loss of CAD 1,968,000, net loss attributable to shareholders of CAD 1,931,000 or CAD 0.04 per basic and diluted share on revenues of CAD 2,376,000 against net loss of CAD 971,000, net loss attributable to shareholders of CAD 872,000 or CAD 0.02 per basic and diluted share on revenues of CAD 2,256,000 a year ago.

BELLUS Health Inc. Announces Sale of ABCP Notes and Settlement of Credit Facilities

BELLUS Health Inc. announced the sale of its ABCP Notes and settlement of its credit facilities. The company sold all of its asset-backed commercial paper notes (ABCP Notes) for a total consideration of $5.3 million and used the proceeds thereof to settle its credit facilities, which were scheduled to mature in April 2016. Net cash generated from these transactions amounted to $150,000. Early settlement of its credit facilities will enable the company to save approximately $150,000 in future interest payments, and fully eliminates its bank indebtedness. The sale of ABCP Notes also eliminates the market risk associated with these assets.

BELLUS Health Inc. Announces Earnings Results for the Third Quarter September 30, 2014

BELLUS Health Inc. announced earnings results for the third quarter September 30, 2014. For the quarter, the company’s revenues amounted to CAD 420,000 compared to CAD 528,000 for the corresponding period the previous year. The decrease is mainly attributable to revenue recorded in the comparative period in relation to the agreement with Asclepios Bioresearch (UK) Limited for the development of BLU8499, which was terminated in October 2013. Net finance income amounted to CAD 53,000 compared to CAD 129,000 for the corresponding period the previous year. The decrease is mainly attributable to a lower increase in the fair value of the ABCP Notes compared to the previous year. Net loss attributable to shareholders was CAD 710,000 or CAD 0.01 per basic and diluted share compared to net profit attributable to shareholders of CAD 1,039,000 or CAD 0.02 per basic and diluted share for the corresponding period the previous year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLU:CN C$1.19 CAD 0.00

BLU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.05 CAD -0.005
Eli Lilly & Co $73.12 USD +1.25
Novartis AG SFr.96.65 CHF -0.05
Pfizer Inc $34.08 USD +0.15
View Industry Companies
 

Industry Analysis

BLU

Industry Average

Valuation BLU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 22.7x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BELLUS HEALTH INC, please visit www.bellushealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.